

Supplementary table 1

Medications defined as psychotropics and used by the included patients.

Pharmacological subgroup	ATC 3rd level	Chemical substance	ATC 5th level
Anti-epileptics	N03A	Carbamazepine	N03AF01
		Valproic acid	N03AG01
		Lamotrigine	N03AX09
		Gabapentin	N03AX12
		Levetiracetam	N03AX14
		Pregabalin	N03AX16
Dopaminergic agents	N04B	Levodopa and decarboxylase inhibitor	N04BA02
		Pramipexole	N04BC05
Antipsychotics	N05A	Haloperidol	N05AD01
		Chlorprothixene	N05AF03
		Zuclopenthixol	N05AF05
		Olanzapine	N05AH03
		Quetiapine	N05AH04
		Risperidone	N05AX08
Anxiolytics	N05B	Diazepam	N05BA01
		Oxazepam	N05BA04
		Bromazepam	N05BA08
		Alprazolam	N05BA12
Hypnotics and sedatives	N05C	Zopiclone	N05CF01
		Zolpidem	N05CF02
		Melatonin	N05CH01
Antidepressants	N06A	Amitriptyline	N06AA09
		Citalopram	N06AB04
		Sertraline	N06AB06
		Escitalopram	N06AB10
		Mirtazapine	N06AX11
		Venlafaxine	N06AX16
		Duloxetine	N06AX21
		Agomelatine	N06AX22
Anti-Dementia drugs	N06D	Donepezil	N06DA02
		Memantine	N06DX01
Other	R06A	Promethazine	R06AD02

Table 1: Anatomical Therapeutic Chemical (ATC). "Chemical substance" represents medications in each ATC-group, which were used by patients in the study population.

Supplementary figure 1




Figure. The prevalence of no polypharmacy, polypharmacy, and excessive polypharmacy in patients using psychotropic medications and patients not using psychotropic medications.